Cargando…

MiRNA Expression in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy

Aims: The aim of the work was to establish potential biomarkers or drug targets by analysing changes in miRNA concentration among patients with Gaucher disease (GD) compared to in healthy subjects. Methods: This study was an observational, cross-sectional analysis of 30 adult participants: 10 contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pawliński, Łukasz, Polus, Anna, Tobór, Ewa, Sordyl, Maria, Kopka, Marianna, Solnica, Bogdan, Kieć-Wilk, Beata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822051/ https://www.ncbi.nlm.nih.gov/pubmed/33375048 http://dx.doi.org/10.3390/life11010002

Ejemplares similares

Specific gene expression in type 1 diabetic patients with and without cardiac autonomic neuropathy
por: Gastol, Joanna, et al.
Publicado: (2020)

The Complexities of Diagnosis with Co-Existing Gaucher Disease and Hemato-Oncology—A Case Report and Review of the Literature
por: Sudul, Paulina, et al.
Publicado: (2023)

Increased nitric oxide availability attenuates high fat diet metabolic alterations and gene expression associated with insulin resistance
por: Razny, Urszula, et al.
Publicado: (2011)

Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis
por: Góralska, Joanna, et al.
Publicado: (2020)

DNA methylation microarrays identify epigenetically regulated lipid related genes in obese patients with hypercholesterolemia
por: Płatek, Teresa, et al.
Publicado: (2020)

Enzyme Replacement in Gaucher Disease
por: Beutler, Ernest
Publicado: (2004)

Case report of dysregulation of primary bile acid synthesis in a family with X-linked adrenoleukodystrophy
por: Płatek, Teresa, et al.
Publicado: (2018)

Case report of endoprosthesis -Y implantation in severe respiratory failure in the MPSII patient; comparison with literature data
por: Gocyk, Wojciech, et al.
Publicado: (2020)

COVID-19 Pandemic and Patients with Rare Inherited Metabolic Disorders and Rare Autoinflammatory Diseases—Organizational Challenges from the Point of View of Healthcare Providers
por: Tobór-Świętek, Ewa, et al.
Publicado: (2021)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022)

Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease
por: van Dussen, Laura, et al.
Publicado: (2014)

Effect of caloric restriction with or without n-3 polyunsaturated fatty acids on insulin sensitivity in obese subjects: A randomized placebo controlled trial()
por: Razny, Urszula, et al.
Publicado: (2015)

Epigenetic Regulation of Processes Related to High Level of Fibroblast Growth Factor 21 in Obese Subjects
por: Płatek, Teresa, et al.
Publicado: (2021)

Carboxylated and undercarboxylated osteocalcin in metabolic complications of human obesity and prediabetes
por: Razny, Urszula, et al.
Publicado: (2016)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
por: Beshlawy, Amal El, et al.
Publicado: (2019)

Down-regulation of Regulatory T-cells in Children With Gaucher Disease Under Enzyme Replacement Therapy
por: Zahran, Asmaa M., et al.
Publicado: (2019)

Evaluation of the Nutritional Status of Gaucher Disease Type I Patients under Enzyme Replacement Treatment
por: Iaccarino Idelson, Paola, et al.
Publicado: (2022)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease
por: Limgala, Renuka Pudi, et al.
Publicado: (2016)

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3
por: Lee, Ni-Chung, et al.
Publicado: (2022)

Targeted Enzymatic VLP‐Nanoreactors with β‐Glucocerebrosidase Activity as Potential Enzyme Replacement Therapy for Gaucher's Disease
por: Chauhan, Kanchan, et al.
Publicado: (2022)

a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy
por: Moraitou, Marina, et al.
Publicado: (2023)

Hematopoietic Stem Cell Transplantation is a cost-effective alternative to enzyme replacement therapy in Gaucher Disease
por: Aboobacker, Fouzia N, et al.
Publicado: (2022)

Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model
por: Vigan, Marie, et al.
Publicado: (2014)

Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients
por: Smid, Bouwien E., et al.
Publicado: (2016)

Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications
por: van Dussen, Laura, et al.
Publicado: (2014)

Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports
por: Amato, Dominick, et al.
Publicado: (2018)

Symmetric, bilateral upper and lower extremity lucent lesions in a patient with Gaucher's disease on enzyme replacement therapy
por: Kuhn, Andrew S., et al.
Publicado: (2020)

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

Gaucher disease type 1: the first experience of enzyme replacement therapy in pediatric practice in Moldova - case report
por: Uşurelu, Natalia, et al.
Publicado: (2021)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Gaucher disease – bone involvement
por: Chis, Bogdan Augustin, et al.
Publicado: (2021)

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
por: Mistry, Pramod K, et al.
Publicado: (2009)

Predictors of the maximal oxygen consumption in adult patients with type 1 diabetes treated with personal insulin pumps
por: Matejko, Bartłomiej, et al.
Publicado: (2021)

Type 1 diabetes outpatient care and treatment effectiveness during COVID-19: A single-center cohort study
por: Kania, Michał, et al.
Publicado: (2023)

Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report
por: Giuffrida, Gaetano, et al.
Publicado: (2016)

Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously
por: Noya, MSoledad, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7oesmq1014rb4fq2k6m00plhuq